MedTrace Logo

Effects of 7-Day Creatine Supplementation on Cognitive Function After High-Intensity Interval Training in Active Young Men

NCT07534293 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-16

No results posted yet for this study

Summary

This study evaluates whether 7-day creatine monohydrate supplementation affects cognitive function after high-intensity interval training (HIIT) in active young men. Twenty participants were assigned to one of four groups: placebo plus exercise, placebo without exercise, creatine 0.1 g/KgBW/day plus exercise, or creatine 0.3 g/KgBW/day plus exercise. Cognitive performance was measured before and after the intervention using visual reaction time, go/no-go visual reaction time, and Trail Making Tests A and B.

Conditions

  • Creatine Supplementation
  • Exercise Ergogenics

Interventions

DRUG

Creatine Monohydrate

Creatine monohydrate supplementation at a dose of 0,1 g/KgBW/day for 7 days.

DRUG

Creatine Monohydrate

Creatine monohydrate supplementation at a dose of 0,3 g/KgBW/day for 7 days.

DRUG

Placebo

Placebo supplementation for 7 days

BEHAVIORAL

High Intensity Interval Training

A bodyweight high-intensity interval training program performed in 2 rounds with 40 seconds work and 20 seconds rest in round 1, and 30 seconds work and 15 seconds rest in round 2, with 30 seconds rest between rounds.

Sponsors & Collaborators

  • Universitas Negeri Malang

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
25 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-07
Primary Completion
2026-02-14
Completion
2026-02-14

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07534293 on ClinicalTrials.gov